Aurinia Pharmaceuticals Inc. (AUPH) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Edmonton, BC, カナダ. 現CEOは Kevin C. Tang.
AUPH を有する IPO日 2014-09-03, 130 名の正社員, に上場 NASDAQ Global Market, 時価総額 $2.13B.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
